检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]浙江中医药大学附属第一医院,杭州310006
出 处:《中华中医药杂志》2017年第1期360-362,共3页China Journal of Traditional Chinese Medicine and Pharmacy
基 金:浙江省中医药科学研究基金计划项目(No.2011ZA028)~~
摘 要:目的:观察利肺健脾方联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法:63例晚期NSCLC患者随机分为两组,治疗组(32例)给予利肺健脾方联合GP或DP方案化疗,对照组(31例)给予GP或DP方案化疗。治疗2个周期进行疗效评价。结果:在瘤灶近期疗效方面,治疗组的有效率和疾病控制率分别为43.8%和65.6%,对照组分别为38.7%和61.3%,两组差异无统计学意义。治疗后治疗组在KPS评分、细胞免疫功能及化疗不良反应方面优于对照组(P<0.05)。结论:利肺健脾方联合化疗治疗晚期NSCLC,可以改善患者的生活质量,提高患者的细胞免疫功能,减轻化疗的不良反应。Objective:To observe the clinical curative effect of Lifei Jianpi(LFJP) Decoction in association with chemotherapy in treating patients with advanced non-small cell lung cancer(NSCLC).Methods:Sixty-three patients with advanced NSCLC were randomly assigned to two groups.The 31 patients in the control group were only treated with chemotherapy of GP or DP regimen,and 32 patients in the treatment group were treated with the same chemotherapy and LFJP Decoction.The clinical efficacy was evaluated after two cycles of treatment.Results:In treatment group,the response rate(RR) was 43.8%,and disease control rate(DCR) was 65.6%.In control group,the RR was 38.7%,and DCR was 61.3%.The difference between two groups was not statistically significant.After treatment,the KPS score,cellular immune function and chemotherapy toxicity in the treatment group were statistically significant compared with that of control group(P〈0.05).Conclusion:LFJP combined with chemotherapy in treating advanced NSCLC can improve their quality of life,enhance their cell-mediated immune function and relive side effects and toxic effects caused by chemotherapy.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.106